share_log

Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5

Cantor Fitzgerald Downgrades Global Blood Therapeutics to Neutral, Lowers Price Target to $68.5

坎托·菲茨杰拉德将全球血液疗法的评级下调至中性,将目标股价下调至68.5美元
Benzinga Real-time News ·  2022/08/09 05:00

Cantor Fitzgerald downgrades Global Blood Therapeutics (NASDAQ:GBT) from Overweight to Neutral and lowers the price target from $75 to $68.5.

坎托·菲茨杰拉德将全球血液疗法(纳斯达克股票代码:GBT)的评级从增持下调至中性,并将目标股价从75美元下调至68.5美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发